title: Monocarboxylate transporter 2 and stroke severity in a rodent model of sleep apnea.
abstract: Stroke is not only more prevalent but is also associated with more severe adverse functional outcomes among patients with sleep apnea. Monocarboxylate transporters (MCT) are important regulators of cellular bioenergetics, have been implicated in brain susceptibility to acute severe hypoxia (ASH), and could underlie the unfavorable prognosis of cerebrovascular accidents in sleep apnea patients. Rodents were exposed to either intermittent hypoxia (IH) during sleep, a characteristic feature of sleep apnea, or to sustained hypoxia (SH), and expression of MCT1 and MCT2 was assessed. In addition, the functional recovery to middle cerebral artery occlusion (MCAO) in rats and hMCT2 transgenic mice and of hippocampal slices subjected to ASH was assessed, as well as the effects of MCT blocker and MCT2 antisense oligonucleotides and siRNAs. IH, but not SH, induced significant reductions in MCT2 expression over time at both the mRNA and protein levels and in the functional recovery of hippocampal slices subjected to ASH. Similarly, MCAO-induced infarcts were significantly greater in IH-exposed rats and mice, and overexpression of hMCT2 in mice markedly attenuated the adverse effects of IH. Exogenous pyruvate treatment reduced infarct volumes in normoxic rats but not in IH-exposed rats. Administration of the MCT2 blocker 4CN, but not the MCT1 antagonist p-chloromercuribenzene sulfonate, increased infarct size. Thus, prolonged exposures to IH mimicking sleep apnea are associated with increased CNS vulnerability to ischemia that is mediated, at least in part, by concomitant decreases in the expression and function of MCT2. Efforts to develop agonists of MCT2 should provide opportunities to ameliorate the overall outcome of stroke.
authors.affiliation: Department of Pediatrics, University of Chicago, Chicago, Illinois 60637, USA.
authors.forename: Yang
authors.initials: Y
authors.lastname: Wang
authors.forename: Shang Z
authors.initials: SZ
authors.lastname: Guo
authors.forename: Arend
authors.initials: A
authors.lastname: Bonen
authors.forename: Richard C
authors.initials: RC
authors.lastname: Li
authors.forename: Leila
authors.initials: L
authors.lastname: Kheirandish-Gozal
authors.forename: Shelley X L
authors.initials: SX
authors.lastname: Zhang
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Brittian
authors.forename: David
authors.initials: D
authors.lastname: Gozal
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D006624:Hippocampus / Q000378:metabolism* / Q000503:physiopathology; D000860:Hypoxia / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D027501:Monocarboxylic Acid Transporters / Q000235:genetics / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012720:Severity of Illness Index; D012891:Sleep Apnea Syndromes / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology; D020521:Stroke / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology
chemical_list: D027501:Monocarboxylic Acid Transporters; C490426:Slc16a7 protein, mouse